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The aim of this project was to study the possible association between maternal infusion treatments during pregnancy 
and variables of fetal development as well as the occurrence of congenital abnormalities (CA) in a case-control design. 
The large population-based data set of the Hungarian Case-Control Surveillance of Congenital Abnormalities 
(HCCSCA) was evaluated based on the medically recorded infusion treatment during pregnancy. Of 22,843 case 
pregnant women who had newborns or fetuses with congenital abnormalities, 112 (0.5%), while of 38,151 control 
pregnant women who had newborn infants without any defects, 262 (0.7%), had infusion treatment during pregnancy.  
Infusion treatment was more frequent in the control group than in the case group with congenital abnormalities 
(adjusted POR with 945 95% CI: 0.7, 0.6-0.9) and there was no higher rate of maternal infusion treatments in any 
congenital abnormality group. Mean gestational age was shorter and mean birth weight was smaller in control newborn 
infants without CA born to mothers with infusion treatment during pregnancy than in the babies of mothers without 
infusion treatment.  The prevalence of mild intrauterine growth retardation was more frequent in the fetuses of 
pregnant women with hyperemesis gravidarum treated with infusion. The results of the study suggest that infusion 
treatment of pregnant women did not associate with a higher risk of congenital abnormalities. In addition, the 
intravenous infusion of drugs has some, but limited efficacy to prevent the adverse effects of hyperemesis gravidarum 
and threatened preterm delivery. 
Key words: Infusion treatment, underlying pregnancy complications, congenital abnormalities, preterm birth, intrauterine growth 
retardation. 
1.  Introduction 
The effect of drugs during pregnancy is determined 
beyond the chemical structure of product, the treatment 
time during gestation, dose, duration of treatment, 
underlying diseases and pregnancy complications, other 
drugs due to their possible interaction and last but not 
least the type of administration: oral, rectal, vaginal, 
ophthalmic, otic, nasal, topical and parenteral [1]. Among 
parenteral medications, subcutaneous, intramuscular and 
intravenous routes can be differentiated [2]. In the latter 
some drugs are administered at once or by slow push, and 
continuous or intermittent intravenous infusion [3]. 
Clinical studies have shown that intravenous infusion of 
certain drugs is more effective than other administrations 
due to immediate drug action [4]; in addition, intravenous 
fluids are used for many sick and injured patients to treat 
dehydration and loss of electrolytes [5].  
Infusion treatment is also used in pregnant women 
particularly for prolonging pregnancy in women at risk 
for preterm delivery [6], with extreme severe nausea-
vomiting (the so-called hyperemesis gravidarum) [7, 8] 
and after surgery large volumes of hypotonic fluid are 
generally given to pregnant women [9, 10]. As Friedman 
and Polifka [11] stated, the effect of infusion treatments 
during pregnancy was rarely studied for fetal 
development, and only the effect of specific drugs used by 
infusion was evaluated [12,13].  
The population-based large data set of the 
Hungarian Case-Control Surveillance of Congenital 
Abnormalities (HCCSCA 1980-1996) [14] is ideal for us to 
check the possible association between maternal infusion 
therapy during pregnancy and the occurrence of 
congenital abnormalities (CAs), in addition to study 
gestational age, birth weight, the proportion of preterm 
birth and low birthweight in control newborn infants 
without CA born to mothers with or without infusion 
therapy.   
2.  Materials and methods 
Cases 
The cases with CAs for the HCCSCA were identified 
from the data set of the Hungarian Congenital 
Abnormality Registry (HCAR) [15]. Notification of cases 
with CAs is compulsory for physicians, and most are 
reported by obstetricians (in Hungary practically all 
deliveries occur in inpatient obstetric units and birth 
attendants are obstetricians) and paediatricians (who 
work in the neonatal units of inpatient obstetric clinics or 
in various inpatient and outpatient paediatric clinics). 
Autopsy was obligatory for all infant deaths and usual in 
stillborn fetuses during the study period. Pathologists sent 
a copy of autopsy report to the HCAR if defects were 
identified in stillbirths and infant deaths. The recorded 
total prevalence of cases with CA diagnosed from the 
second trimester of pregnancies through the age of one 
year was 35 per 1000 informative offspring (liveborn infants, 
stillborn fetuses and electively terminated pregnancies 
due to malformed fetuses) and about 90% of major CAs 
were reported to the HCAR during 17 years of the study 
period [15].  
There were two restrictions at the selection of cases 
for the HCCSCA. Firstly, only cases that were reported 
during the first three months after birth or termination of 
pregnancy were selected. This shorter time between 
“pregnancy end” and data collection increases the 
accuracy of information about pregnancy history without 
undue loss of power since 77% of cases were reported 
during this time window to the HCAR. Secondly, three Int. J. Med. Sci. 2005 2  138
mild CAs (such as congenital dislocation of hip based on 
Ortolani click, congenital inguinal hernia, and large 
haemangioma), minor anomalies-variants (e.g., umbilical 
hernia, hydrocele, small haemangioma) and 
CA-syndromes of known Mendelian or chromosomal 
origin were excluded. 
Controls 
Controls  were defined as newborn infants without 
CAs and they were selected from the National Birth 
Registry of the Central Statistical Office for the HCCSCA. 
In general, two control newborn infants were matched to 
every case according to sex, birth week, and district of 
parents' residence. 
Collection of exposure data 
E x p o s u r e  d a t a  w e r e  o b t a i n e d  f r o m  t h e  f o l l o w i n g  
three sources: (i) Retrospective maternal self-reported 
information. A post-paid questionnaire, explanatory letter 
along with a list of medicinal products (drugs and 
pregnancy supplements) and diseases, and a printed 
informed consent were mailed immediately after the 
selection of cases and controls to the mothers. The 
questionnaire requested information, among others, on 
medicinal product intakes, pregnancy complications, 
maternal diseases and treatments including infusion 
during pregnancy according to gestational month. To 
standardize the answers, mothers were asked to read the 
enclosed lists of drugs and diseases before they replied. In 
addition, mothers of cases were asked to give a signature 
for the enclosed informed consent which authorised us to 
record their name and address. (ii) Prospective medically 
recorded data. Mothers were also asked to send us the 
antenatal care logbook and discharge summaries of 
hospitalisation during pregnancy together with the filled-
in questionnaire and signed informed consent. The mean 
± S.D. time elapsed between the pregnancy end and return 
of the data package was 3.5 ± 1.2 and 5.2 ± 2.9 months in 
the groups of cases and controls, respectively. (iii) 
Supplementary data collection in non-respondent 
mothers. Regional district nurses were asked to visit and 
to question all no respondent mothers of cases and 200 no 
respondent control mothers at home. Regional nurses 
used the same questionnaire through a personal interview 
and evaluated the available medical records. District 
nurses did not visit all no respondent control mothers 
because the ethical committee considered this follow-up to 
be disturbing to the parents of these healthy children [16]. 
Thus, information was available on 96.3% (84.4% from 
reply, 11.9% from visit) of cases and on 83.0% (82.6% from 
r e p l y ,  0 . 4 %  f r o m  v i s i t )  o f  c o n t r o l s .   D a t a  f r o m  t h e  
antenatal care logbook were available in 88.4% of cases 
and in 93.8% of controls. The informed consent document 
was signed by 98.4% of case mothers. Personal identifiers 
(i.e. name and address) were deleted from the record of 
cases if their mothers did not give informed consent keep 
them. The personal data of controls are not recorded in 
the HCCSCA.  
The fourth step was the evaluation of maternal 
infusion in five different aspects. 
1) The source of information. All infusion treatments 
were medically recorded in the discharge summary, 
because pregnant women with severe nausea-vomiting 
and threatened preterm delivery were hospitalized. 
2) Medication used through infusion and the intake of 
other drugs. Pregnancy supplements (such as calcium, 
iron, and vitamins) and infusion used for labour induction 
were excluded from this analysis.  
3)  Time of infusion according to g estational age. 
Gestational age was calculated from the first day of last 
menstrual period and three time intervals were 
considered: (i) the first month of pregnancy, which is 
before organogenesis; (ii) the second and third months of 
gestation, considered the most sensitive, and the so-called 
critical period for most major CAs; and (iii) the fourth to 
ninth months of gestation. If pregnant women had 
infusion twice or more during the study pregnancy, only 
one treatment was analysed according to the following 
priority: 2-3, 1, 4-9 months.   
4) Gestational age and birth weight were analysed in 
newborn infants of control mothers with or without 
infusion treatment. These variables were also medically 
recorded. Cases with CAs were excluded from this 
analysis because CAs may have a more drastic effect for 
these variables than infusion treatment. 
5) Potential confounding factors, as maternal age, birth 
order, marital and employment status of mothers (as 
indicators of socioeconomic status), pregnancy 
complications and drug uses were evaluated. 
Statistical analysis   
Results were analysed with the SAS version 8.02 
statistical software package (SAS Institute Ins., Cary, 
North Caroline, USA). First, the prevalence of infusions 
was compared between the study groups and crude 
prevalence odds ratios (POR) with 95% confidence 
interval (95% CI) were calculated. Second, quantitative 
confounders such as maternal age, birth order, were 
compared using Student t test while POR with 95% CI 
were calculated for marital status and chi square test for 
employment status. Third, pregnancy complications were 
compared between case and control groups in 
unconditional logistic regression model. Fourth, the 
distribution of gestational age according to the infusion 
treatment was evaluated using chi square test. Fifth, the 
prevalence of maternal infusion treatment in 24 CA-
groups was compared with the frequency of this 
treatment in their all matched controls and adjusted POR 
with 95% CI for potential confounders were evaluated in a 
conditional logistic regression model. Sixth, the 
prevalence of maternal infusion treatment in the CA-
groups was compared with the prevalence of this 
treatment in total controls as reference using 
unconditional logistic regression model. Finally, mean 
birth weight and gestational age of control newborn 
infants born to mothers with or without infusion 
treatment were compared in linear logistic regression 
model, while the proportion of preterm birth and low 
birthweight were compared in unconditional logistic 
regression model. 
3.  Results 
During the study period, 2,146,574 babies were born 
in Hungary; therefore 38,151 controls represented 1.8% of 
the Hungarian births. In the control group, 262 (0.69%) 
pregnant women had infusion. The case group consisted 
of 22,843 malformed offspring and 112 (0.49%) pregnant 
women were treated by infusion during pregnancy. Thus 
the infusion treatment was less frequent in the case group 
(adjusted POR with 95% CI: 0.7, 0.6-0.9).  
The characteristics of mothers are shown both in 
total and infusion treated case and control groups in Table Int. J. Med. Sci. 2005 2  139
1. It is worth mentioning that pregnant women with 
infusion were younger with lower birth order than the 
mothers in the total groups. Mean maternal age did not 
show significant difference between case and control 
pregnant women with infusion, while the mean birth 
order was lower in the group of case mothers with 
infusion. There was no obvious difference in the 
proportion of unmarried women and in the distribution of 
employment status between case and control mothers 
with infusion. 
The prevalence of pregnancy complications is shown 
in Table 2. These data reflect the three main reasons of 
maternal infusion: (i) threatened preterm delivery in 
about half of mothers; (ii) hyperemesis gravidarum; and 
(iii) surgical interventions. In addition, there was a higher 
prevalence of threatened abortions in the mothers with 
infusion compared with the mothers of total groups. 
However, there was no significant difference in the 
prevalence of pregnancy complications between the case 
and control groups with infusion. 
The distribution of infusion according to the month 
of gestation in the case and controls groups is shown in 
Table 3. There were two peaks of infusion treatments. The 
first peak was connected with the treatment of 
hyperemesis gravidarum in the second and third months 
o f  g e s t a t i o n .  T h e  r e a s o n  o f  s e c o n d  p e a k  i n  t h e  i n f u s i o n  
treatments can be explained by threatened preterm 
delivery in the seventh and eighth month of gestation. 
Mothers with surgical interventions are not evaluated 
here because these pregnant women were evaluated 
previously (10). As we previously mentioned, labour 
induction was also excluded from this analysis. There was 
no significant difference in the monthly distribution of 
infusions between controls and cases (χ28=7.55; p=0.48) 
and in the frequency of infusion during the second-third 
months of pregnancy (χ21=0.4; p=0.51).  
The reason of infusion for hyperemesis gravidarum 
was fluid replacement combined with oral treatment of 
thiethylperazine, dimenhydrinate and vitamin B6. In 
general Saletanol D5® solution (sodium chloride 4.5 g, 
glucose 50 g and alcohol 50 g in 1000 ml solution with a 
speed of 30-40 drops/min which means 0.19/bw/hour of 
alcohol) or Ringer lactate® solution (sodium chloride 5.55 
g, potassium chloride 0.3 g, calcium chloride 0.28 g, 
magnesium chloride 0.09 g, sodium lactate 5.04 g in 1000 
ml with a speed of 120-150 drops/min) were used for this 
treatment. The reason of infusion for threatened preterm 
delivery was the so-called tocolysis, terbutaline 
(Bricanyl®) (5 mg per 1000 ml isotonic sodium chloride 
solution, 1 ml contains 5 µg for 8 h with a starting speed of 
10  µg/min contained by 5 µg/min) and fenoterol 
(Partusisten®) (0.5 mg per 250-500 ml 5% glucose solution 
with a speed of 0.5-3.0 µg / m i n )  w e r e  u s e d  f o r  t h i s  
purpose sometimes combined by verapamil (Verapamil®). 
The occurrence of other frequently used drugs 
(antibiotics, analgesics, etc.) did not show significant 
differences between case and control mothers with 
infusion.  
The prevalence of infusion in 14 CA-groups 
(including 2 or more cases) was compared with the 
frequency of infusion in their all matched controls and 
adjusted POR with 95% CI for confounding factors were 
calculated in conditional logistic regression model (Table 
4). There was no a higher prevalence of infusion during 
the study pregnancy in any CA-groups. On the other hand 
the maternal infusion during the study pregnancy showed 
a lower occurrence in two CA-groups: hypospadias and 
multiple CAs (which include heterogeneous CA-entities). 
Thus, the adjusted POR with 95% CI for the prevalence of 
infusion was also lower in the total group of cases with 
CAs. It is worth focusing the second and third months of 
gestation, the critical period of most major CAs. We did 
not find a higher prevalence of infusion treatment in any 
CA group, but the number of case mothers was limited.  
The prevalence of maternal infusion treatment in the 
CA-groups was compared with the prevalence of this 
treatment in the total control group as well. This approach 
showed a higher adjusted POR with 95% CI for renal 
a/dysgenesis (4.4, 1.4-14.1), however, this possible 
association was based on 3 cases and two offspring had 
mothers with infusion after the third month of gestation 
(i.e. the critical period of this CA-group). The lower 
prevalence of infusion in the mothers with children 
affected with hypospadias (0.4, 0.2-0.8) and multiple CAs 
(0.2, 0.1-0.8) was confirmed. 
The distribution of gestational age and birth weight 
groups and their mean ± S.D. were evaluated only in 
control pregnant women with or without infusion (Table 
5). Both gestational age (adjusted t = 5.4, p<0.001) and 
birth weight (adjusted t = 7.6, p<0.001) were significantly 
lower in pregnant women with infusion than in pregnant 
women without infusion. These trends were in agreement 
with the higher rate of preterm birth (16.4% vs. 9.1%) and 
low birthweight (12.6% vs. 5.6%) of newborn infants born 
to mother with infusion.  
These differences were more obvious in women who 
had infusion in the sixth-ninth month of gestation: mean 
gestational age was 38.1 ± 2.6 and 39.4 ± 2.0 week, while 
mean birth weight 2,941 ± 529 and 3,277 ± 311 gram in 
women with and without infusion, respectively. On the 
other hand the mean gestational age (39.4 ± 2.5 vs. 39.4 ± 
2.0 week) in control women with or without infusion was 
similar between the second and fifth months due to 
hyperemesis gravidarum. However, there was a 
significant reduction in mean birth weight (3,162 ± 596 vs. 
3,276 ± 511 gram) and it was reflected in a higher 
proportion of low birthweight (10.4% vs. 5.7%). 
4.  Discussion 
Our study is the first to evaluate the possible 
association in general between the effect of maternal 
infusion treatments during pregnancy and the different 
variables of fetal development. On the one hand, there 
was a lower prevalence of maternal infusion in the group 
of total CAs, and within them, of hypospadias and 
m u l t i p l e  C A s .  T h u s ,  w e  w e r e  n o t  a b l e  t o  d e t e c t  a n y  
teratogenic potential of infusion treatment during 
pregnancy. On the other hand, mean gestational age was 
shorter and mean birth weight was smaller in control 
newborn infants without CA born to mothers with 
infusion treatment during the study pregnancy than in the 
babies of mothers without infusion treatment. Thus, 
infusion of drugs used for the prevention of threatened 
preterm delivery seems to have a limited efficacy. 
However, the ratio of threatened preterm delivery was 1 
in 3.6 among pregnancy complications instead of the ratio 
of preterm birth: 1 in 1.8, therefore nearly half of 
threatened preterm deliveries was effectively treated, 
therefore it was not inefficient. In addition, intrauterine 
growth retardation was found in newborn infants born to 
mothers with hyperemesis gravidarum on the contrary of 
infusion treatments.  Int. J. Med. Sci. 2005 2  140
The strengths of the HCCSCA's data set are (i) the 
large and (ii) population-based cohort including 374 
pregnant women with infusion treatment (iii) in an 
ethnically homogeneous European (Caucasian) 
population. (iv) The data of infusion were prospectively 
collected and medically recorded, thus recall bias can be 
excluded. (v) Cases with CA and their controls without 
CAs were matched, (vi) main confounders were known, 
(vii) birth weight and gestational age were medically 
recorded, and (viii) there was a good validity of CA-
diagnoses due to the results of recent medical 
examinations [14]. However, this data set has also 
limitations. Though the response rate was similar in 
controls (83%) and cases (84%), there was an active follow-
up, i.e. a home visit in all no respondent case mothers but 
only in 200 no respondent control mothers. However, the 
use of drugs in control mothers with no response did not 
differ significantly from the rate of control pregnant 
women who responded [16]. Multiple comparison may 
produce a statistically significant association (p<0.05) in 
every 20th estimation because of chance and we explain 
the higher occurrence of renal a/dysgenesis after infusion 
treatment at the comparison of this CA group with the 
total control group by chance. In addition this 
possible association was based on 3 cases because only 
one was born to the mother who had infusion in the 
second month of gestation, i.e. during the critical period of 
renal a/dysgenesis. The type of drugs obviously has a 
greater impact for fetuses than the route of administration 
[17]. Thus it is not possible to evaluate the impact of an 
administration route (namely infusion in this study) 
without taking into account the different drugs. However, 
the major reason of infusion in pregnant women with 
hyperemesis gravidarum is the fluid replacement. The 
teratogenic potential of antiemetic drugs used in Hungary 
parallel with infusion was evaluated previously. A weak 
association was found between thiethylperazine and cleft 
lip ± palate [18], there was no teratogenic potential of 
dimenhydrinate [19], while vitamin B6 showed a 
protective effect for cardiovascular CAs [20]. The other 
main indication of infusion therapy was threatened 
preterm delivery and it was combined with terbutaline, 
fenoterol and verapamil. In general the time of this 
treatment was the last trimester of pregnancy (i.e. after the 
organogenesis). We need further studies to evaluate in 
general the efficacy of different drugs according to 
administration route in pregnant women.  
The intravenous route is used for the administration 
of medications when immediate or special drug action is 
required due to the severity of pathological conditions. 
Nevertheless, a teratogenic potential of infusion treatment 
and/or drugs, in addition underlying pregnancy 
complications (e.g. dehydration) during pregnancy was 
not detectable in our study. The dehydration in 
experimental animal (mouse) investigations caused CAs, 
particularly isolated cleft palate [21, 22]. In fact, mothers 
who had infusion treatment later delivered boys with a 
lower risk for hypospadias and multiple CAs. These 
unexpected findings need further studies.  
The gestational age was shorter and birth weight was 
lower in control infants without CA born to mothers with 
infusion treatment during pregnancy. These findings may 
indicate the limited value of this treatment because these 
pregnant women had also a significantly higher 
proportion of preterm birth. In addition, babies born to 
mothers with hyperemesis gravidarum showed 
intrauterine growth retardation on the contrary of 
infusion treatment. Similar findings were not found in 
women with severe nausea and vomiting during 
pregnancy [23].  
In conclusion, the results of our study suggest that 
infusion treatment of pregnant women did not associate 
with a higher risk for CAs. The intravenous infusion of 
drugs have some, but limited efficacy to prevent the 
adverse effect of hyperemesis gravidarum and threatened 
preterm delivery.  
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Tables 
Table 1. Characteristics of mothers 
Cases Controls  Variables 
Total 
(N=22,843) 
Infusion 
(N=112) 
Total 
(N=38,151) 
Infusion 
(N=262) 
Comparison between  
case and control mothers with 
infusion 
Continuous  Mean S.D. Mean S.D.  Mean S.D.  Mean  S.D.  t-test  p-value 
Maternal age, yr  25.5 5.3 24.3 5.2  25.5 4.9  25.1  5.2  1.34  0.18 
Birth order  1.6 1.0 1.3 0.8  1.6 0.9  1.5  0.9  2.31  0.02 
Categorical  No. % No. %  No. %  No.  %  POR  95%CI 
Unmarried  1,269     5.6  9  8.0  1,471  3.9  8  3.1  2.8  1.0- 7.4 
Employment status                 
Professionals  1,901     8.3  11  9.8  4,353  11.4  27  10.3 
Managerial 4,968  21.8  29  25.9  10,134  26.6  74  28.2 
Skilled worker  6,329  27.7 30 26.8  11,690  30.6  77  29.4 
Semiskilled  worker  3,869 16.9  16 14.3 5,783 15.2 34  13.0 
Unskilled worker  1,503 6.6  8 7.1  1,859 4.9 14  5.3 
Others  4,273 18.7  18 16.1 4,332 11.4 36  13.7 
 
 
χ25 = 1.19 
 
 
 
  p = 0.95 
 
Table 2. Prevalence of pregnancy complications 
Cases Controls  Comparison  between 
Total 
(N=22,843) 
Infusion 
(N=112) 
Total 
(N=38,151) 
Infusion 
(N=262) 
case and control mothers with 
infusion 
Pregnancy complications 
No. %  No.  % No.  % No. %  POR  95%CI 
Nausea-vomiting  (excessive) 1,746  7.6  33  29.5  3,869  10.1 92 35.1  0.8  0.5-  1.2 
Threatened  abortion  3,501 15.3 39 34.8 6,512  17.1  81  30.9  1.2 0.7-  1.9 
Preeclampsia* 1,768  7.7  11 9.8 3,159  8.3  28  10.7  0.9 0.4-  1.9 
Threatened  preterm  delivery  2,603 11.4 53 47.3 5,446  14.3  135  51.5  0.8 0.5-  1.3 
Placental disorders  297  1.3 5 4.5 593  1.6  8  3.1  1.5 0.5-  4.6 
Anaemia  3,240 14.2 17 15.2 6,356  16.7  48  18.3  0.8 0.4-  1.5 
Surgery 67  0.3  4  3.6  91  0.2  12  4.6  0.8 0.2-  2.4 
 *including hypertension, proteinuria and oedema alone as well 
Table 3. Gestational month distribution of infusion (onset) and the name of infusion solution, in addition drugs used for treatment 
without infusion due to labour induction. 
Gestational month  Cases  Infusion Controls  Infusion 
      No.    %        No.    %   
I.  0  0.0               -  3  1.1                 - 
II.  18  16.1  Saletanol D5   16, 
Ringer lactate     2 
43  16.4  Saletanol D5   37, 
Ringer lactate     6 
III.  12  10.7  Saletanol D5   11, 
Ringer lactate     1 
33  12.6  Saletanol D5    28, 
Ringer lactate      4, 
Infusamine 10% 1 
IV.  6  5.4  Saletanol D5      3, 
Fenoterol            2, 
Glucose 20%      1 
20  7.6  Saletanol D5    12, 
Fenoterol            8 
V.  6  5.4  Fenoterol            4, 
Terbutaline        2 
16  6.1  Fenoterol          10, 
Terbutaline        5, 
Glucose 20%     1 
VI.  13  11.6  Terbutaline        8, 
Fenoterol           5, 
(Verapamil 3)        
27  10.3  Terbutaline      15, 
Fenoterol         12, 
(Verapamil 4)     
VII.  39  34.8  Terbutaline      27, 
Fenoterol        12, 
(Verapamil 4)       
69  26.3  Terbutaline      41, 
Fenoterol        28, 
(Verapamil    13) 
VIII-IX. 18  16.1  Terbutaline      12, 
Fenoterol          6, 
(Verapamil  6) 
51  19.5  Terbutaline      35, 
Fenoterol         16, 
(Verapamil     12) 
Total  112 100.0    262 100.0   
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Table 4. Occurence of infusion in 14 CA-groups including at least two cases and in their matched controls, in addition adjusted 
prevalence odds ratios (POR) with 95% confidence interval (95%CI) 
Total  Entire pregnancy  II-III months  Study groups 
No. No. % POR*  95% CI  No. % POR*  95% CI 
Isolated  CAs                 
  Neural-tube defects   1,202  2  0.2 0.5  0.1 - 2.7  0  0.0 -  - 
  Cleft lip± palate   1,374  10  0.7 1.3  0.6 - 3.0  3  0.2 3.1   0.3 - 34.0
  Rectal/anal atresia/stenosis  220  2  0.9 2.8   0.2 - 31.9 1  0.5 1.5   0.1 - 25.6
  Renal a/dysgenesis  104  3  2.9 2.6   0.5 - 14.7 1  1.0 -  - 
  Obstructive urinary CAs  502  3  0.6 1.0  0.2 - 4.1  0  0.0 -  - 
  Hypospadias   3,038  9  0.3 0.4  0.2 - 0.8  2  0.1 0.4  0.1 - 1.9 
  Undescended testis   2,051  7  0.3 0.6  0.2 - 1.4  3  0.2 1.1  0.2 - 5.1 
  Exomphalos/gastroschisis  238  2  0.8 4.5   0.6 - 35.9 0  0.0 -  - 
  Cardiovascular CAs   4,479  35  0.8 1.1  0.7 - 1.7  12  0.3 1.5  0.7 - 3.3 
  Clubfoot   2,424  11  0.5 0.9  0.4 - 2.1  4  0.2 0.7  0.2 - 2.4 
  Poly/syndactyly  1,744  11  0.6 1.0  0.5 - 2.2  2  0.1 0.6  0.1 - 3.3 
  CAs of musculoskeletal system 525  3  0.6 0.4  0.1 - 1.6  0  0.0 -  - 
  Other isolated CAs**   3,593  12  0.3 0.5  0.3 - 1.0  2  0.1 0.2  0.0 - 0.7 
Multiple CAs   1,349  2  0.2 0.1  0.0 - 0.6  0  0.0 -  - 
Total cases  22,843 112 0.5 0.7  0.6 - 0.9  30  0.1 0.7  0.4 - 1.1 
Total controls  38,151 262 0.7 - 76  0.2 - 
* adjusted for maternal age (<25 years, 25-29 years, and 30 years or more), birth order (first delivery or one or more previous deliveries), maternal employment status 
(professional, managerial, skilled worker versus semiskilled worker, unskilled worker, housewife, other), use of other drugs during pregnancy (as a dichotomous 
variable) and maternal disorders (as a dichotomous variable) in conditional logistic regression model 
**congenital hydrocephalus, posterior cleft palate, buphthalmos, unspecified CA of ear, branchial cyst, bronchial stenosis, pyloric stenosis, stenosis of small intestine, 
cystic kidney, diaphragmatic CA, arthrogryposis, ichthyosis congenita 
Table 5. Distribution of birth weight and gestational age groups in the control group of mothers with or without infusion 
Total  Gestational age (week)  - 36  37 - 41  42 - 
With infusion  Without infusion 
Birth-weight (g)  With 
No. 
Without 
No. 
With 
No. 
Without 
No. 
With 
No. 
Without 
No. 
No. % Mean  S.D. No.  % Mean  S.D. 
- 2499  25  1,258  8  825  0  51  33  12.6  34.4  3.0  2,134  5.6  35.7  3.2 
2500 – 3499  18  2,166  147  19,039  14  1,456  179  68.3  38.9  1.8  22,661  59.8  39.1  1.8 
3500 -   0  29  38  10,736  1,222  2,329 50  19.1 40.7 1.4  13,094  34.6 40.5 1.1 
Total  No.  43  3,453 193  30,600 26  3,836 262  100.0  38.7 2.6  37,889  100.0 39.4 2.0 
  % 16.4 9.1 73.7  80.8 9.9 10.1                 
Birth weight  Mean  2,287  2,486 3,152  3,325 3,406  3,617    3,035  571     3,278  511 
  S.D.  580 434 426 430 480 486                 
Crude POR with 95% CI for low birthweight (outcome = low birth weight, exposure = infusion): 2.4 (1.7 – 3.5). 
Adjusted POR for low birthweight (adjusted for birth order, maternal age and employment status, maternal disorders and use of drugs): 2.3 (1.6 – 3.4). 
Crude POR with 95% CI for preterm birth (outcome = preterm birth, exposure = infusion): 2.0 (1.4 – 2.7). 
Adjusted POR for preterm birth (adjusted for birth order, maternal age and employment status, maternal disorders and use of drugs): 1.8 (1.3 – 2.6). 